Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

Détails

ID Serval
serval:BIB_E6F9D4B5BE56
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species
Périodique
Journal of Clinical Microbiology
Auteur(s)
Odds  F. C., Motyl  M., Andrade  R., Bille  J., Canton  E., Cuenca-Estrella  M., Davidson  A., Durussel  C., Ellis  D., Foraker  E., Fothergill  A. W., Ghannoum  M. A., Giacobbe  R. A., Gobernado  M., Handke  R., Laverdiere  M., Lee-Yang  W., Merz  W. G., Ostrosky-Zeichner  L., Peman  J., Perea  S., Perfect  J. R., Pfaller  M. A., Proia  L., Rex  J. H., Rinaldi  M. G., Rodriguez-Tudela  J. L., Schell  W. A., Shields  C., Sutton  D. A., Verweij  P. E., Warnock  D. W.
ISSN
0095-1137
Statut éditorial
Publié
Date de publication
08/2004
Peer-reviewed
Oui
Volume
42
Numéro
8
Pages
3475-82
Notes
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't --- Old month value: Aug
Résumé
Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC(2)) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode +/- one dilution range across all 17 laboratories. MIC(2) at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.
Mots-clé
Antifungal Agents/*pharmacology Aspergillus/*drug effects/isolation & purification Candida/*drug effects/isolation & purification Echinocandins Fluconazole/pharmacology Geography Humans Laboratories/*standards Microbial Sensitivity Tests/*standards Peptides/*pharmacology *Peptides, Cyclic Quality Control Reproducibility of Results
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/02/2008 12:39
Dernière modification de la notice
20/08/2019 16:10
Données d'usage